Disc Medicine (NASDAQ:IRON) Shares Down 3% – Here’s What Happened

Shares of Disc Medicine, Inc. (NASDAQ:IRONGet Free Report) fell 3% during mid-day trading on Friday . The company traded as low as $51.20 and last traded at $50.82. 173,913 shares were traded during trading, a decline of 52% from the average session volume of 360,581 shares. The stock had previously closed at $52.41.

Wall Street Analyst Weigh In

IRON has been the subject of several analyst reports. TD Cowen assumed coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Scotiabank raised their price target on Disc Medicine from $73.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 3rd. Morgan Stanley reiterated an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research report on Friday, March 7th. Stifel Nicolaus raised their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $89.10.

Read Our Latest Report on IRON

Disc Medicine Stock Down 2.7 %

The stock has a market cap of $1.76 billion, a P/E ratio of -12.82 and a beta of 0.73. The company’s 50 day moving average price is $56.62 and its two-hundred day moving average price is $55.94.

Disc Medicine (NASDAQ:IRONGet Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. As a group, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $66.01, for a total value of $844,333.91. Following the completion of the transaction, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. The trade was a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mona Ashiya sold 202,146 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34. Following the sale, the director now directly owns 208,742 shares in the company, valued at $11,332,603.18. This trade represents a 49.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 359,408 shares of company stock worth $20,027,286 in the last three months. Corporate insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

A number of institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC boosted its stake in Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Disc Medicine during the 4th quarter valued at $40,000. Tower Research Capital LLC TRC boosted its position in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC purchased a new position in Disc Medicine during the 3rd quarter worth $131,000. Finally, Quantbot Technologies LP acquired a new position in Disc Medicine during the 3rd quarter valued at about $146,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Read More

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.